RARE files Form 144 for $90K stock sale set for 20 June 2025

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. (RARE) has filed a Form 144 with the U.S. Securities and Exchange Commission to notify the market of a proposed secondary sale of its equity.

• Securities: 2,405 shares of common stock
• Acquisition date & type: Restricted stock received on 05/15/2025 from the issuer
• Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004
• Planned sale date: Approximately 06/20/2025 on the NASDAQ exchange
• Estimated market value: US $89,922.95
• Total shares outstanding: 94,542,035  ⇒  proposed sale equals roughly 0.0025% of shares outstanding
• Prior 3-month sales: None reported

The filing is marked as LIVE and contains the standard representation that the seller is unaware of any undisclosed material adverse information. No additional financial data or strategic developments are included in this notice. Given the very small size of the transaction relative to Ultragenyx’s share base, the filing appears routine with limited market impact.

Insights

Financial Analyst

TL;DR: Sale of 2,405 RARE shares (~$90K) is immaterial; neutral impact.

The Form 144 discloses a planned divestiture totalling less than three-thousandths of one percent of Ultragenyx’s outstanding equity. Such a minor volume is unlikely to influence liquidity or price discovery. No new operational or financial information accompanies the notice, and the filer reports no prior sales in the past quarter. From a valuation or sentiment standpoint, the disclosure is routine and should not alter the investment thesis.

Corporate Governance Expert

TL;DR: Routine Rule 144 compliance filing; governance implications negligible.

Form 144 exists to ensure transparency when affiliates or other covered persons intend to sell restricted or control securities. The blank “Relationship to Issuer” field limits insight into the seller’s identity, yet the document still fulfils disclosure requirements: stating share count, acquisition method, and broker details. Absence of past-quarter sales and explicit confirmation of no undisclosed adverse information indicate procedural adherence. There are no governance red flags or concentration risks stemming from this small transaction.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2405	89922.95	94542035	06/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/15/2025	Restricted Stock	ISSUER			2405	05/15/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Ultragenyx (RARE) shares are proposed to be sold in the Form 144?

The notice covers 2,405 common shares.

What is the aggregate market value of the shares Ultragenyx plans to sell?

The filing cites an aggregate value of approximately US $89,922.95.

When is the Ultragenyx share sale expected to occur?

The approximate sale date listed is 06/20/2025.

What percentage of Ultragenyx’s outstanding shares does the sale represent?

2,405 shares versus 94,542,035 outstanding equals roughly 0.0025% of shares outstanding.

Which broker will handle the proposed Ultragenyx share sale?

Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Were any Ultragenyx shares sold by the filer in the past three months?

No. The Form 144 states “Nothing to Report” for prior three-month sales.